Texas Taxpayers to Give Cancer Research Another $3 Billion

Voters approved a measure to double the state’s Cancer Prevention & Research Institute of Texas.

Written byKerry Grens
| 2 min read
austin texas cprit cancer funding

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: © ISTOCK.COM, DAVEL5957

The Cancer Prevention & Research Institute of Texas, a state-run program with a $3 billion budget, will receive another $3 billion after voters approved a ballot measure on Tuesday (November 5), Science reports. The influx of funds means that CPRIT will receive $300 million a year for the next 10 years.

“Everyone at CPRIT appreciates the confidence Texans place in us to guide the state toward a cancer-free future,” CPRIT CEO Wayne Roberts says in a statement.

The agency began in 2009 with the goal of fueling science, bringing in top talent, developing new therapeutics, and encouraging cancer prevention. CPRIT encountered scandal in its early years when an audit discovered that $56 million in grants had been awarded without proper review, while other applications were left in limbo. This led officials to suspend the agency for 10 months beginning in December 2012 and overhaul is procedures ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies